Lenz Therapeutics eyes better vision than AbbVie, Orasis with $80M+ for three PhIII trials
Lenz Therapeutics thinks it can deliver a better eye drop than AbbVie’s Vuity and Orasis Pharmaceuticals’ CSF-1, under FDA review. And the San Diego biotech has $83.5 million to test those ambitions in three Phase III trials.
The late-stage studies are underway and will read out data on about 800 patients toward the end of this year and early 2024, president and CEO Eef Schimmelpennink told Endpoints News on Tuesday morning. The financing will bankroll the company for at least two and a half years, he added.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,800+ biopharma pros reading Endpoints daily — and it's free.